Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...